The ability to target CCL2 - a monocyte recruiting chemokine expressed in the tumour microenvironment65, myocarditis66, myocardial infarction67 and stroke68 - in addition to other chemokines makes these evasins potentially useful in disrupting the chemokine network in these diseases. This evidence concerns the gene CCL2 and neoplasm.